Bexovid is the world’s first branded generic drug for mild to moderate Covid-19 treatment, manufactured by Beximco Pharmaceutical Ltd., a Good Manufacturing Practice product, certified by the United States Food and Drug Administration (FDA), European Union FDA, Australian FDA, Brazilian FDA and Philippine FDA. CONTRIBUTED PHOTO
ON Jan. 7, 2022, Biocare Lifesciences Inc., the exclusive importer and distributor of Bexovid (150 mg Nirmatrelvir tablet and 100 mg Ritonavir tablet) in the Philippines, received a compassionate special permit after the approval of the Food and Drug Administration (FDA) for mild to moderate Covid-19 treatment.
The Nirmatrelvir and Ritonavir combination was an innovative product of Pfizer that was approved by the United States FDA under the brand name, Paxlovid.
"Being able to offer Bexovid to Covid-19 patients and health care partners is an exciting step for Biocare," said Dileep Tiwari, the managing director of Biocare Lifesciences Inc. "With the approval and launch of Bexovid in the Philippines, we're currently ready to satisfy our objective and mission in acquiring quality and affordable medicine in this time of the pandemic."
'Having Bexovid is a great addition to the company's product portfolio for Covid-19. This is after we launched Remdesivir and Favirpiravir in 2020 and Temziva (Tocilizumab), Cipmolnu (Molnupiravir), Sepsivac (Mycobacterium W) [and] Pulmosis (Pirfenidone) in 2021 here in the Philippines to assist in the fight against Covid-19," added Tiwari.